Amgen Inc (AMGN)
What changed in recent filings
- Prolia segment 14% → 8%Jun 30, 2024 → Jun 30, 2026
- Institutions — 1 added · 3 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Amgen Inc recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Aug 4, 2026Revenue +9.5% YoY · EPS $4.37Released after the close: Aug 4 close → Aug 5 close, the stock moved +4.6% · over the same window, market -0.2% · sector +0.5%
- 26Q1Released Apr 30, 2026Revenue +5.8% YoY · EPS $3.34Released after the close: Apr 30 close → May 1 close, the stock moved -4.7% · over the same window, market +0.3% · sector -1.0%
- 25Q4Released Feb 3, 2026Revenue +8.6% YoY · EPS $2.46Released after the close: Feb 3 close → Feb 4 close, the stock moved +8.2% · over the same window, market -0.5% · sector +0.1%
- 25Q3Released Nov 4, 2025Revenue +12.4% YoY · EPS $5.93Released after the close: Nov 4 close → Nov 5 close, the stock moved +7.8% · over the same window, market +0.3% · sector +0.2%
The next earnings release is estimated around Nov 3, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Amgen Inc
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 6 → 2026 Q2: 6 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Amgen Inc
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)0.30% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Coxunder 0.01% of portfolio · held as of 2019 Q1 or earlier
- PRIMECAP Management1.45% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)0.02% of portfolio · held as of 2019 Q1 or earlier
- Capital World Investors1.24% of portfolio · since 2024 Q3
- Bridgewater Associates0.03% of portfolio · since 2025 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
One of the first biotech companies. It is simultaneously developing a GLP-1 obesity drug and a biosimilars business.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Amgen Inc is classified under the Biotech & Health sector. See peers below.
Amgen Inc key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Amgen Inc vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
AMGN segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
2 quarters with a different segment breakdown were omitted (filing basis changed).
ETFs holding Amgen Inc
Per SEC N-PORT · 2026-07-31 · by weight · factual
AMGN on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
AMGN FAQ
What is Amgen Inc (AMGN)?
One of the first biotech companies. It is simultaneously developing a GLP-1 obesity drug and a biosimilars business.
What sector is Amgen Inc in?
Amgen Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Amgen Inc's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 9.1%, Operating margin 35.0%, Net margin 23.0%, ROE 89.1%, Debt-to-equity 4.90x. Definitions and interpretation are available on Stocklore.
Where can I analyze Amgen Inc (AMGN) stock?
On Stocklore you can see AMGN's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.